Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Generics Saved U.S. Over a Trillion Dollars

By Drug Discovery Trends Editor | August 3, 2012

TRENTON, N.J. (AP) – Growing use of generic medicines has reduced U.S. health care spending by more than $1 trillion over the past decade, according to an industry-funded study.

The fourth annual report, produced for the Generic Pharmaceutical Association, found use of generic prescription drugs in the U.S. saved about $193 billion last year alone. That amount was up 22% from the $158 billion in savings from generics in 2010, and was more than three times the $60 billion in savings in 2002, the report states.

The report notes that using inexpensive generic versions of pricier brand-name prescription drugs now saves the country about $1 billion every other day.

Last year, nearly 80% of the 4 billion prescriptions dispensed in this country were generic drugs. Because of their cheaper prices, those drugs accounted for just 27% of total U.S. spending on prescription medicines. In categories where both branded medicines and generic drugs are available, consumers opted to get the generic version 94% of the time last year, the report noted.

Use of generic drugs has been growing steadily in this country, fueled by both patients and insurers looking to save money, since the copycat pills were first allowed under a 1984 law called the Hatch-Waxman Act. Once there are multiple generic versions of a brand-name drug available in pharmacies, the price for all those generics generally drops to 80% to 90% less than the brand-name price.

Growth in generic use has been accelerating in the last several years as the first generics arrived for an unprecedented number of popular drugs, taken daily by millions of people, that were launched a decade or more ago and are now seeing their patents expire. Those multi-billion-dollar-a-year drugs include Lipitor for high cholesterol, blood thinner Plavix, antidepressant Effexor XR, osteoporosis pill Fosamax and Aricept for Alzheimer’s disease symptoms.

The report, which was prepared by health data firm IMS Health, notes drugs for heart conditions and central nervous system disorders such as depression and convulsions account for 57% of the annual savings.

Generic drugs are chemically equivalent to brand-name drugs and work the same as the brand-name medicines in nearly all patients. They are cheaper because, unlike the pharmaceutical companies that create brand-name medicines, generic drugmakers don’t have to spend roughly a decade and a $1 billion on laboratory and then patient tests to prove the drugs are safe and effective.

Date: August 2, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE